Recombinant Human Nuclear Receptor Subfamily 1 Group I Member 3 (NR1I3) Protein (His-SUMO)

Name: Recombinant Human Nuclear Receptor Subfamily 1 Group I Member 3 (NR1I3) Protein (His-SUMO)
Brand: Beta LifeScience
SKU: BLC-09981P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Nuclear Receptor Subfamily 1 Group I Member 3 (NR1I3) Protein (His-SUMO) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q14994
Target Symbol	NR1I3
Synonyms	CAR; CAR BETA; CAR1; CARA; Constitutive activator of retinoid response; constitutive active receptor; Constitutive active response; constitutive androstane nuclear receptor variant 2; constitutive androstane nuclear receptor variant 3; constitutive androstane nuclear receptor variant 4; constitutive androstane nuclear receptor variant 5; Constitutive androstane receptor; MB67; MGC97144; NR1I3; NR1I3_HUMAN; Nuclear receptor subfamily 1 group I member 3; orphan nuclear hormone receptor; Orphan nuclear receptor MB67; Orphan nuclear receptor NR1I3
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His-SUMO
Target Protein Sequence	ASREDELRNCVVCGDQATGYHFNALTCEGCKGFFRRTVSKSIGPTCPFAGSCEVSKTQRRHCPACRLQKCLDAGMRKDMILSAEALALRRAKQAQRRAQQTPVQLSKEQEELIRTLLGAHTRHMGTMFEQFVQFRPPAHLFIHHQPLPTLAPVLPLVTHFADINTFMVLQVIKFTKDLPVFRSLPIEDQISLLKGAAVEICHIVLNTTFCLQTQNFLCGPLRYTIEDGARVSPTVGFQVEFLELLFHFHGTLRKLQLQEPEYVLLAAMALFSPDRPGVTQRDEIDQLQEEMALTLQSYIKGQQRRPRDRFLYAKLLGLLAELRSINEAYGYQIQHIQGLSAMMPLLQEIC
Expression Range	2-351aa
Protein Length	Partial
Mol. Weight	55.7kDa
Research Area	Transcription
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital responsive element module of the human CYP2B6 gene and the CYP3A4 xenobiotic response element.
Subcellular Location	Nucleus. Cytoplasm. Cytoplasm, cytoskeleton.
Protein Families	Nuclear hormone receptor family, NR1 subfamily
Database References	HGNC: 7969 OMIM: 603881 KEGG: hsa:9970 STRING: 9606.ENSP00000356958 UniGene: PMID: 30225717 Phosphomimetic substitution of Thr-38 with Asp increased co-immunoprecipitation of the CAR DNA Binding Domain with CAR Ligand Binding Domain in Huh-7 cells. The underlying molecular mechanism that regulates CAR activation is its homodimer-monomer-heterodimer conversion; the monomer and homodimer are phosphorylated at Thr-38 and inactive. PMID: 29133527 Results suggest that TRIM24 is a novel coactivator of the CAR that is involved in cell- and/or promoter- selective transactivation. PMID: 29101097 An overview of NR1I2 and NR1I3 pharmacogenetic studies in various therapeutic fields. PMID: 29199543 replication confirmed at genome-wide significance the association of loci at FOXE1 with hypothyroidism, and PDE8B, CAPZB and PDE10A with serum TSH. A total of 12 SNPs seemed to explain nearly 7% of the serum TSH variation PMID: 28777242 Dual ligands of CAR/PXR show distinct gene regulation patterns by regulating cross-talk between CAR and PXR. PMID: 27197997 Data suggest both PXR and CAR are expressed in testis/Sertoli cells; exposure of Sertoli cells (in vitro model of blood-testis barrier) to PXR or CAR ligands (including antiretroviral drugs) up-regulates expression of Pgp/ABCB1, BCRP, and MRP4. (PXR = pregnane X receptor; CAR = constitutive androstane receptor; Pgp/ABCB1 = P-glycoprotein ABCB1; BCRP = breast cancer resistance protein; MRP4 =multidrug resistance protein 4) PMID: 28970358 Genome-wide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARalpha in primary human hepatocytes has been presented. PMID: 26994748 These data provide new insights into the regulation by CAR of glycolytic and lipogenic genes and on pathogenesis of steatosis PMID: 27180240 Integrative analysis of four RNA-Seq datasets and differential expression revealed for the first time, splicing alterations of SLC39A14 and NR1I3 in hepatocellular carcinoma. PMID: 26711644 These results reveal both novel and known targets of hCAR and support the role of hCAR in maintaining the homeostasis of metabolism and cell proliferation in the liver. PMID: 26275810 The homozygous variant genotype of MPJ6_1I3008 is associated with a significant reduced risk of neonatal hyperbilirubinemia in females. PMID: 26188155 Around 42.5% of the overall interindividual variability in warfarin dose requirements was explained : VKORC1 genotype accounted for 29.6%, CYP2C9 genotype for 4.3%, age for 3.6%, the CYP4F2 genotype for 3.3%, and CAR/HNF4alpha (rs2501873/rs3212198) for 1.7% PMID: 25356900 It is suggested that the functions of PXR, CAR and AhR may be closely implicated in the pathogeneses of metabolic vascular diseases, such as hyperlipidemia, atherogenesis, and hypertension. PMID: 24859622 Suggest that PXR and CAR double humanized mice are more sensitive rifampcin induction of cytochrome P450 and UDP-glucuronosyltransferases. PMID: 25835148 PRMT5 enhances transcriptional activity of constitutive androstane receptor.PRMT5 is a gene-selective co-activator for CAR. PMID: 25721668 The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor beta and contributes to the development of experimental dermal fibrosis. PMID: 25155144 Donor CYP3A5, NR1I3 gene polymorphisms. PMID: 24351870 ubiquitin-proteasomal regulation of CCRP and HSP70 are important contributors to the regulation of cytoplasmic CAR levels, and hence the ability of CAR to respond to PB or PB-like inducers PMID: 24789201 The polymorphisms investigated in PPARA (rs1800206), RXRA (rs11381416), and NR1I2 (rs1523130) did not influence the lipid-lowering efficacy and safety of statin and our results show the possible influence of NR1I3 genetic variant on the safety of statin. PMID: 24232815 miR-137 is a crucial regulator of cancer response to doxorubicin treatment PMID: 23934188 The CAR variant, which results in a poor metabolizer phenotype, could account for a higher degree of external genitalia virilization in 21OHD females. PMID: 22978668 Gadd45B protects the liver through two entirely different processes: binding MKK7 to block damaging signal transduction or binding CAR to coactivate anabolic transcription. (Review) PMID: 24104474 Activated p38 MAPK is required for CAR to selectively activate a set of genes that encode drug-metabolizing enzymes. PMID: 23539296 Common genetic variants in the xenobiotic transport and metabolism regulator genes PXR and CAR do not have a significant association with multiple myeloma risk. PMID: 23303387 CYP2B6 516G>T (P < 0.0001) and CAR rs2307424 C>T (P = 0.002) were significantly related to efavirenz plasma concentrations. PMID: 23172109 Constitutive androstane receptor-mediated enzyme induction in the liver depends on the presence of beta-catenin at the time of xenobiotic treatment. PMID: 23578392 Report CAR expression in human parotid glands. PMID: 23614276 Polymorphisms in the RXRA and NR1I3 genes influence lipid profile in a Southern Brazilian population. PMID: 23079705 DAX-1 as a novel and potent constitutive androstane receptor (CAR) corepressor and suggest that DAX-1 functions as a coordinate hepatic regulator of CAR's biological function. PMID: 22896671 DP97 was found to be a gene (or promoter)-selective co-activator for hCAR PMID: 22910411 phenobarbital-mediated down-regulation of miR-122 is an early and important event in the AMPK-dependent CAR activation and transactivation of its target genes PMID: 22815988 In severe intrahepatic cholestasis of pregnancy the CAR expression in placenta syncytiotrophoblastic cells increased appreciably, which may be involved in the maintenance of placenta barrier function and protection. PMID: 21733368 CAR transactivates ABCG2 through the DR5 motif located in its distal promoter in hepatocytes and the motif prefers CAR to pregnane X receptor. PMID: 22093699 activated ERK1/2 interacts with CAR and represses dephosphorylation of Thr-38, providing a cell signal-regulated mechanism for CAR activation. PMID: 21873423 CAR mRNA levels were unchanged while protein levels were markedly induced in obstructive cholestasis as compared with the controls. PMID: 21359593 These data indicate that genetic variability in CYP2B6 and constitutive androstane receptor contributes to early treatment discontinuation for efavirenz-based antiretroviral regimens PMID: 21715435 These findings provide the first evidence for P-glycoprotein regulation by pregnane X receptor and constitutive androstane receptor at the human blood brain barrier. PMID: 21517853 results suggest that HNF4alpha plays an important role in the constitutive expression of hepatic UGT2B7, and CAR acts as a negative regulator by interfering with HNF4alpha binding activity PMID: 21415305 constitutive androstane receptor (hCAR) mediated the CYP2B6 induction by cigarette smoke extract in Hep2G cells; data suggest that smoking up-regulates CYP2B6 through hCAR in vivo PMID: 20966044 FXR activation in obstructive cholestasis might worsen liver injury by hijacking a protective mechanism regulated by CAR and provides a new molecular explanation to the pathophysiology of cholestasis. PMID: 21296199 CCAAT/enhancer-binding protein alpha (C/EBPalpha) and hepatocyte nuclear factor 4alpha (HNF4alpha) synergistically cooperate with constitutive androstane receptor to transactivate the human cytochrome P450 2B6 (CYP2B6) gene PMID: 20622021 Four haplotypes were determined for CAR single nucleotide polymorphisms. PMID: 20218903 Data observed that OSM positively augmented the CAR and UGT1A1 expressions and CAR-mediated signaling in vivo and in vitro, through cross talk between the nuclear CAR receptor and the plasma membrane OSM receptor, via the MAPK cascade. PMID: 20197307 Results characterize the conserved threonine 38 of human constitutive active/androstane receptor (CAR) as the primary residue that regulates nuclear translocation and activation of CAR. PMID: 19858220 CAR antagonizes ER-mediated transcriptional activity by squelching limiting amounts of p160 coactivators, such as SRC-1 and GRIP-1. PMID: 12114525 Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. PMID: 12130689 Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. PMID: 12181452 identified as a key regulator of acetaminophen metabolism and hepatotoxicity PMID: 12376703 Substantial interindividual differences exist in hepatic constitutive androstane receptor expression; a 240-fold interindividual variability in hepatic mRNA levels has been detected. PMID: 12485946

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.